您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报 (医学版) ›› 2018, Vol. 56 ›› Issue (2): 14-17.doi: 10.6040/j.issn.1671-7554.0.2017.771

• 临床医学 • 上一篇    下一篇

复方阿胶浆对化疗所致小细胞肺癌骨髓抑制的影响

周勇,侯华英,徐英,姜玉华   

  1. 山东大学第二医院肿瘤防治中心, 山东 济南 250033
  • 发布日期:2022-09-28
  • 通讯作者: 姜玉华. E-mail:jiangyuhua@sdu.edu.com
  • 基金资助:
    山东省自然科学基金(ZR2017MH027)

Efficacy of compound e-jiao slurry on marrow suppression of small-cell lung cancer after chemotherapy

ZHOU Yong, HOU Huaying, XU Ying, JIANG Yuhua   

  1. Cancer Centre, The Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Published:2022-09-28

摘要: 目的 观察复方阿胶浆对化疗所致小细胞肺癌患者骨髓抑制的影响。 方法 将确诊的135例小细胞肺癌患者分为对照组(n=70)和治疗组(n=65),对照组给予EP方案常规化疗,治疗组在EP方案常规化疗同时口服复方阿胶浆,3次/d,20 mL/次;观察两组患者化疗完成情况及化疗后的血红蛋白(Hb)、血小板(PLT)、白细胞(WBC)和中性粒细胞(NEUT)变化等骨髓抑制情况。 结果 治疗组的化疗完成率高于对照组;治疗组的WBC、NEUT下降幅度明显低于对照组(P<0.05)。 结论 复方阿胶浆可降低WBC及NEUT骨髓抑制发生率,并改善化疗所致小细胞肺癌患者的WBC及NEUT减少情况。

关键词: 复方阿胶浆, 小细胞肺癌, 化疗, 骨髓抑制

Abstract: Objective To observe the efficacy of compound e-jiao slurry on chemotherapy-resulted marrow suppression of small-cell lung cancer. Methods A total of 135 patients with small-cell lung cancer were divided into the control group(n=70)and treatment group(n=65). The control group was treated with EP chemotherapy program, while the treatment group took the compound e-jiao slurry(20 mL every time and three times every day)companying with EP chemotherapy program. The chemotherapy completion rates of patients were calculated. The marrow suppression, especially the change of hemoglobin, platelet, white blood cell(WBC)and neutrophil(NEUT)counts were observed. Results The chemotherapy completion rate of the treatment group is higher than that of the control group. The decreasing values of WBC and NEUT counts in these two groups were statistically significant(P<0.05). Conclusion Compound e-jiao slurry decreases the incidence rate of the chemotherapy-resulted marrow suppression(WBC, NEUT)and relieves the decrease of WBC and NEUT counts.

Key words: Compound e-jiao slurry, Small-cell lung cancer, Chemotherapy, Marrow suppression

中图分类号: 

  • R730.5
[1] 孙广玉,王淑燕,宋相孔,等. 肺癌患者放化疗后肺部感染的相关因素分析[J].中华医院感染学杂志, 2014, 24(18): 4488-4490. SUN Guangyu, WANG Shuyan, SONG Xiangkong, et al. Related factors for pulmonary infections in lung cancer patients after chemoradiotherapy[J]. Chin J Nosocomiol, 2014, 24(18): 4488-4490.
[2] 李常青. 肿瘤化疗医院感染的相关因素分析及防范措施探讨[J].中华医院感染学杂志, 2013, 23(10): 2316-2318. LI Changqing. Related factors of nosocomial infections in tumor patients undergoing chemotherapy and exploration of prevention measures[J]. Chin J Nosocomiol, 2013, 23(10): 2316-2318.
[3] 李伟伟,崔艳慧,蔡卫梅. 肺癌患者化疗期间发生感染的相关危险因素分析[J].中华医院感染学杂志, 2013, 23(6): 1277-1279. LI Weiwei, CUI Yanhui, CAI Weimei. Risk factors for infections in lung cancer patients during chemotherapy[J]. Chin J Nosocomiol, 2013, 23(10): 2316-2318.
[4] Li Y, He H, Yang L, et al. Therapeutic effect of Colla corii asini on improving anemia and hemoglobin compositions in pregnant women with thalassemia[J]. Int J Hematol, 2016, 104(5): 559-565.
[5] 管燕,李艳,王丽杰,等.恶性肿瘤化疗后骨髓抑制患者复方阿胶浆应用观察[J].山东医药, 2013, 53(47): 51-52.
[6] Wang D, Ru W, Xu Y, et al. Chemical constituents and bioactivities of Colla corii asini[J]. Drug Discov Ther, 2014, 8(5): 201-207.
[7] 徐振晔,朱晏伟,周卫东,等.双黄升白冲剂与粒-巨噬细胞集落刺激因子治疗肺癌化疗骨髓抑制44例临床研究[J].中医杂志, 2003, 44(12): 919-921.
[8] Wu H, Yang F, Cui S, et al. Hematopoietic effect of fractions from the enzyme-digested colla corii asini on mice with 5-fluorouracil induced anemia[J]. Am J Chin Med, 2007, 35(5): 853-866.
[9] 郑筱祥,杨勇,叶剑锋,等.东阿阿胶的升白作用及机制研究[J].中国现代应用药学, 2005, 22(2): 102-105. ZHENG Xiaoxiang, YANG Yong, YE Jianfeng, et al. The mechanism of Donkey-hide gelatin in increasing leukocyte [J]. The Chinese Journal of Modern Applied Pharmacy, 2005, 22(2): 102-105.
[10] 游捷,单孟俊,赵慧,等.中西医结合治疗91例老年晚期非小细胞肺癌疗效观察[J].中国中西医结合杂志, 2012, 32(6): 774-778. YOU Jie, SHAN Mengjun, ZHAO Hui, et al. Clinical study of integrative treatment for ninety-one elderly patients with advanced non-small cell lung cancer[J]. CJITWM, 2012, 32(6): 774-778.
[11] 黄超,黎丽群,吴耀忠,等.芪胶升白胶囊防治恶性肿瘤化疗后骨髓抑制疗效的Meta分析[J].山东医药, 2015, 55(24): 66-68.
[12] 敖曼,连相尧,刘承一,等.参芪扶正注射液对肺癌化疗患者造血功能和免疫功能的影响[J].山东医药, 2012, 52(3): 60-61.
[13] 段哲萍,于新江,吕艳玲,等.复方苦参注射液对非小细胞肺癌放疗患者放射性肺损伤及骨髓抑制的防治作用及机制[J].山东医药, 2016, 56(32): 81-83.
[14] 邓艳,柯晴,毛艳.参芪扶正注射液对晚期非小细胞肺癌化疗患者造血和免疫功能的干预作用[J].中国老年学杂志, 2015, 35(21): 6142-6144.
[15] 王中奇,邓海滨,吴继,等.双黄升白颗粒治疗肺癌化疗后骨髓抑制的临床研究[J].上海中医药杂志, 2013, 47(6): 35-37. WANG Zhongqi, DENG Haibin, WU Ji, et al. Clinical research of “Shuanghuang Shengbai Granule” on arrest of bone marrow in patients with lung cancer after chemotherapy[J]. Shanghai Journal of Traditional Chinese Medicine, 2013, 47(6): 35-37.
[16] 韩海帆,张路,张淹,等. NIRS法快速测定复方阿胶浆中总黄酮、总皂苷和可溶性固形物[J].中草药, 2013, 44(17): 2397-2403. HAN Haifan, ZHANG Lu, ZHANG Yan, et al. Rapid determination of total flavonoids, total saponins, and soluble solid content in Fufang Ejiao Syrup by NIRS[J]. Chinese Traditional and Herbal Drugs, 2013, 44(17): 2397-2403.
[17] Liu M, Tan H, Zhang X, et al. Hematopoietic effects and mechanisms of Fufang ejiao jiang on radiotherapy and chemotherapy-induced myelosuppressed mice[J]. J Ethnopharmacol, 2014, 152(3): 575-584.
[18] 陈慧慧,尤金花,田守生,等.复方阿胶浆药理及临床研究概况[J].中国中药杂志, 2012, 37(20): 3021-3023. CHEN Huihui, YOU Jinhua, TIAN Shousheng, et al. Overview of pharmacological and clinical study on compound Ejiao Jiang[J]. China Journal of Chinese Materia Medica, 2012, 37(20): 3021-3023.
[19] Wu H, Ren C, Yang F, et al. Extraction and identification of collagen-derived peptides with hematopoietic activity from Colla Corii Asini[J]. J Ethnopharmacol, 2016, 182: 129-136.
[20] Wang D, Liu M, Cao J, et al. Effect of Colla corii asini( E’jiao)on D-galactose induced aging mice[J]. Biol Pharm Bull, 2012, 35(12): 2128-2132.
[21] 王慧娟,闫相涛,路平,等.伊立替康联合顺铂与依托泊苷联合顺铂方案一线治疗广泛期小细胞肺癌的多中心临床研究结果[J].中国癌症杂志, 2011, 21(10): 783-788. WANG Huijuan, YAN Xiangtao, LU Ping, et al. Irinotecan plus cisplatin versus etoposide plus cisplatin as the first-line therapy for extensive-disease small cell lung cancer: preliminary results of a multicenter clinical study[J]. China Oncology, 2011, 21(10):783-788.
[22] 杨长良,马丽霞,孙双燕,等.依托泊苷联合顺铂治疗有效患者继续原方案不同时间维持治疗小细胞肺癌患者的疗效和不良反应[J].中华肿瘤杂志, 2016, 38(6): 454-459. YANG Changliang, MA Lixia, SUN shuangyan, et al. Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer[J]. Chin J Oncol, 2016, 38(6): 454-459.
[23] 尹良伟,马海英,王颖,等.顺铂联合依托泊苷或伊立替康及拓扑替康一线治疗小细胞肺癌的比较研究[J].中华肿瘤防治杂志, 2013, 20(10): 782-785. YIN Liangwei, MA Haiying, WANG Ying, et al. Cisplation combined with etoposide irinotecan and topotecan respectively for patients with small cell lung cancer as first-line treatment [J]. Chin J Cancer Prev Treat, 2013, 20(10): 782-785.
[24] 罗洁,李爱武,吴凤英,等. NIP与EP方案一线治疗167例晚期复合性小细胞肺癌的回顾性分析[J].肿瘤, 2012, 32(3): 194-198. LUO Jie, LI Aiwu, WU Fengying, et al. Navelbine-ifosfamide-cisplatin versus etoposide-cisplatin as the first-line treatment of advanced combined small-cell lung cancer: restrospective analysis of 167 cases [J]. Tumor, 2012, 32(3): 194-198.
[25] 黄慧强,王潇潇. 重组人粒-巨噬细胞集落刺激因子临床新应用进展[J].中华血液学杂志, 2012, 33(5): 429-431.
[1] 黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[2] 赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[3] 徐年兴,魏东,乔俊杰,战炳炎. CD8+、IL-6和PaO2对不可切除ⅢB/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[4] 山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[5] 刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45.
[6] 李永,崔书君,杨飞,张凡,殷晓霞. 基于增强MRI的亚区域影像组学模型可预测乳腺癌患者新辅助化疗后的病理完全反应[J]. 山东大学学报 (医学版), 2025, 63(1): 81-89.
[7] 张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.
[8] 王蕾,向淇,刘学伍. 伴系统性硬化症、类风湿关节炎的副肿瘤神经综合征1例[J]. 山东大学学报 (医学版), 2023, 61(7): 118-120.
[9] 韩明勇,于晓黎,曾放平,谢兵,芦兰,瞿家权,江璧锋,唐斯晗,谭洁,梁瑾,钟龙辉,王柳,赵宣植. CT引导经皮肺穿刺肿瘤内化疗技术流程[J]. 山东大学学报 (医学版), 2023, 61(11): 11-19.
[10] 阮祥燕,程姣姣,杜娟,谷牧青. 卵巢组织冷冻保存[J]. 山东大学学报 (医学版), 2022, 60(9): 24-30.
[11] 秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[12] 陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.
[13] 马瑞杰,朱良明,左太阳,李春海,张楠,孙志钢. 微波消融治疗非小细胞肺癌根治术后肺寡转移瘤的预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 63-68.
[14] 刘会宁,彭军,任迎春,杨光,王文豪,刘金锋,田勍. 34例胸腔镜下肺楔形切除与21例肺段切除对位于肺段P区的ⅠA1期非小细胞肺癌治疗比较[J]. 山东大学学报 (医学版), 2022, 60(11): 38-43.
[15] 丁子琛,王浩桦,周立雯,丛慧文,李承圣,包绮晗,杨毅,王廉源,王素珍,石福艳. 基于贝叶斯累加回归树模型的非小细胞肺癌患者个性化疗效研究[J]. 山东大学学报 (医学版), 2022, 60(10): 92-98.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!